Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer By Ogkologos - April 29, 2025 829 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory... March 18, 2021 More Evidence that One HPV Vaccine Dose Protects against Cancer-Causing Infections June 3, 2022 Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated... August 20, 2025 10 Ways the Inflation Reduction Act will Impact Cancer Care August 18, 2022 Load more HOT NEWS 10 Things Diet Soda Does to Your Body If You Drink... GreaterGood Is Helping UMN Fight Social Injustice with Scholarship for Underrepresented... Grabbing the Perfect Gift FDA Grants Accelerated Approval to Tucatinib with Trastuzumab for Colorectal Cancer
